• Ran-Yi Liu, Li-Zhi Wu, Bi-Jun Huang, Jia-Ling Huang, Yan-Ling Zhang, Miao-La Ke, Jun-Mei Wang, Wei-Ping Tan, Ru-Hua Zhang, Han-Kui Chen, Yi-Xin Zeng, and Wenlin Huang.
• State Key Laboratory for Oncology in South China, Cancer Center, Sun Yat-sen University, 651 Dong-feng Road East, Guangzhou 510060, China.
• Virus Res. 2005 Sep 1; 112 (1-2): 24-31.

AbstractThe causative agent of severe acute respiratory syndrome (SARS) has been identified as SARS-associated coronavirus (SARS-CoV), but the prophylactic treatment of SARS-CoV is still under investigation. We constructed a recombinant adenovirus containing a truncated N-terminal fragment of the SARS-CoV Spike (S) gene (from--45 to 1469, designated Ad-S(N)), which encoded a truncated S protein (490 amino-acid residues, a part of 672 amino-acid S1 subunit), and investigated whether this construct could induce effective immunity against SARS-CoV in Wistar rats. Rats were immunized either subcutaneously or intranasally with Ad-S(N) once a week for three consecutive weeks. Our results showed that all of the immunized animals generated humoral immunity against the SARS-CoV spike protein, and the sera of immunized rats showed strong capable of protecting from SARS-CoV infection in vitro. Histopathological examination did not find evident side effects in the immunized animals. These results indicate that an adenoviral-based vaccine carrying an N-terminal fragment of the Spike gene is able to elicit strong SARS-CoV-specific humoral immune responses in rats, and may be useful for the development of a protective vaccine against SARS-CoV infection.

39 keywords...

hide…